CERo Therapeutics Holdings Inc. (Nasdaq: CERO) has announced the dosing of the second patient in the first cohort of its Phase 1 clinical trial for CER-1236, a novel cellular immunotherapy targeting acute myeloid leukemia $(AML.AU)$. The trial is being conducted at the Sarah Cannon Research Institute at the Colorado Blood Cancer Institute in Denver, with Dr. Yazan Migdady as the principal investigator. This development marks a significant milestone in the clinical evaluation of CER-1236, which is designed to employ phagocytic mechanisms in engineered T cell therapeutics. The company reports promising pharmacokinetic results from the first patient, indicating rapid and significant expansion of CER-1236 cells post-infusion. Further protocol-specified evaluations regarding safety, pharmacodynamic, pharmacokinetic, and efficacy endpoints are ongoing, with progress updates anticipated as the study continues.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.